|
Next revision
|
Previous revision
|
responses_to_ai:technological_inevitability:incentivized_technologies_not_pursued:vaccine_challenge_trials [2023/03/31 00:39]
jeffreyheninger created |
responses_to_ai:technological_inevitability:incentivized_technologies_not_pursued:vaccine_challenge_trials [2023/06/23 18:54] (current)
jeffreyheninger Fixing a broken link |
| ====== Resisted Technological Temptation: Vaccine Challenge Trials ====== | ====== Resisted Technological Temptation: Vaccine Challenge Trials ====== |
| |
| Human challenge trials for vaccines involve giving volunteer vaccine candidates, then deliberating exposing them to the disease, to test the efficacy of a vaccine candidate more quickly than standard vaccine trials. | //Published 30 March, 2023. Last updated 30 March, 2023.// |
| |
| Challenge trials are not a technological temptation which has been fully resisted: they have been used for dozens of diseases, including some recently. They are a technological temptation which has been significantly slowed in response to ethical concerns. | Human challenge trials for vaccines involve giving volunteers vaccine candidates, then deliberating exposing them to the disease, to test the efficacy of a vaccine candidate more quickly than standard vaccine trials. |
| |
| For COVID-19, if challenge trials had been done faster, we estimate that they could have allowed vaccines to be developed a few months more quickly. The value resisted by slowing this technological temptation is trillions of dollars and hundreds of thousands or millions of lives lost. | Challenge trials are not a technological temptation which has been fully resisted: they have been used for dozens of diseases, including some recently. They have been significantly slowed in response to ethical concerns. |
| | |
| | For COVID-19, if challenge trials had been done faster, we estimate that they could have allowed vaccines to be developed a few months more quickly, which could have saved trillions of dollars and hundreds of thousands or millions of lives lost. |
| |
| ===== Details ===== | ===== Details ===== |
| During the 1800s, challenge trials for various diseases were done with varying ethical and scientific standards. Some were done on the physician himself or on other medical practitioners, who presumably knew what they were doing to themselves. Others were done on children, prisoners, or hospital patients.((Machemer. //A Brief History of Human Challenge Trials.// Smithsonian Magazine. (2020) [[https://www.smithsonianmag.com/science-nature/brief-history-human-challenge-trials-180976556/]]. \\ Jamrozik & Selgelid. //History of Human Challenge Studies.// Human Challenge Studies in Endemic Settings. (2021) [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431914/]].)) If people died in these studies, there was often significant public and professional backlash.(("To deliberately inject a poison of known high degree of virulency into a human being, unless you obtain that man’s sanction, is not ridiculous, it is criminal." - William Osler, 1898.)) In 1900, Walter Reed developed the first written consent form which included a statement of the study’s risks for challenge trials involving yellow fever in Cuba for the US Army. This study showed that mosquitoes transmit yellow fever, but 4 participants died, including the only woman and one of the doctors conducting the studies.((Machemer. //A Brief History of Human Challenge Trials.// Smithsonian Magazine. (2020) [[https://www.smithsonianmag.com/science-nature/brief-history-human-challenge-trials-180976556/]].)) Public outcry in the US terminated the study. | During the 1800s, challenge trials for various diseases were done with varying ethical and scientific standards. Some were done on the physician himself or on other medical practitioners, who presumably knew what they were doing to themselves. Others were done on children, prisoners, or hospital patients.((Machemer. //A Brief History of Human Challenge Trials.// Smithsonian Magazine. (2020) [[https://www.smithsonianmag.com/science-nature/brief-history-human-challenge-trials-180976556/]]. \\ Jamrozik & Selgelid. //History of Human Challenge Studies.// Human Challenge Studies in Endemic Settings. (2021) [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431914/]].)) If people died in these studies, there was often significant public and professional backlash.(("To deliberately inject a poison of known high degree of virulency into a human being, unless you obtain that man’s sanction, is not ridiculous, it is criminal." - William Osler, 1898.)) In 1900, Walter Reed developed the first written consent form which included a statement of the study’s risks for challenge trials involving yellow fever in Cuba for the US Army. This study showed that mosquitoes transmit yellow fever, but 4 participants died, including the only woman and one of the doctors conducting the studies.((Machemer. //A Brief History of Human Challenge Trials.// Smithsonian Magazine. (2020) [[https://www.smithsonianmag.com/science-nature/brief-history-human-challenge-trials-180976556/]].)) Public outcry in the US terminated the study. |
| |
| During the 1900s, the scale of medical research often increased more quickly than the ethics of medical research. The worst abuses of challenge trials were done during WWII by Germany and Japan. In response, the Nuremberg Code of 1947 established the first international rules for medical research involving human subjects.((//Nuremberg Code.// United States Holocaust Memorial Museum. (Accessed March 21, 2023) [[https://www.ushmm.org/information/exhibitions/online-exhibitions/special-focus/doctors-trial/nuremberg-code]].)) There was also some unethical research done in the West during and after WWII. For example, hepatitis challenge trials at the Willowbrook School from 1954-1971 were done on mentally disabled children.((Berkich. //Case: Willowbrook Experiment.// CUNY (2002) [[https://www.qcc.cuny.edu/socialsciences/ppecorino/medical_ethics_text/chapter_7_human_experimentation/case_study_willowbrook_experiments.htm]].)) In the early 1970s, concern about unethical medical research, including the Willowbrook study, Tuskegee Syphilis Study, Fernald State School trials, and Jewish Chronic Disease Hospital case,((Moon. //The History and Role of Institutional Review Boards: A Useful Tension.// AMA Journal of Ethics (2009) [[https://journalofethics.ama-assn.org/article/history-and-role-institutional-review-boards-useful-tension/]].)) led Congress to pass the National Research Act of 1974 which created IRBs.((A more detailed history of IRBs is more complicated, with some institutions adopting similar review practices decades earlier and some institutions resisting IRBs for decades afterwards.)) IRBs review all potential medical research and determine if it is ethical to proceed. | During the 1900s, the scale of medical research often increased more quickly than the ethics of medical research. The worst abuses of challenge trials were done during WWII by Germany and Japan. In response, the Nuremberg Code of 1947 established the first international rules for medical research involving human subjects.((//Nuremberg Code.// United States Holocaust Memorial Museum. (Accessed March 21, 2023) [[https://www.ushmm.org/information/exhibitions/online-exhibitions/special-focus/doctors-trial/nuremberg-code]].)) There was also some unethical research done in the West during and after WWII. For example, hepatitis challenge trials at the Willowbrook School from 1954-1971 were done on mentally disabled children.((Berkich. //Case: Willowbrook Experiment.// CUNY (2002) [[https://www.qcc.cuny.edu/socialsciences/ppecorino/medical_ethics_text/chapter_7_human_experimentation/case_study_willowbrook_experiments.htm]].)) In the early 1970s, concern about unethical medical research, including the Willowbrook study, Tuskegee Syphilis Study, Fernald State School trials, and Jewish Chronic Disease Hospital case,((Moon. //The History and Role of Institutional Review Boards: A Useful Tension.// AMA Journal of Ethics (2009) [[https://journalofethics.ama-assn.org/article/history-and-role-institutional-review-boards-useful-tension/2009-04]].)) led Congress to pass the National Research Act of 1974 which created IRBs.((A more detailed history of IRBs is more complicated, with some institutions adopting similar review practices decades earlier and some institutions resisting IRBs for decades afterwards.)) IRBs review all potential medical research and determine if it is ethical to proceed. |
| |
| Dozens of human challenge trials have been approved by IRBs, including for malaria,((Sauerwein et al. //Experimental human challenge infections can accelerate clinical malaria vaccine development.// Nature Reviews Immunology **11**. (2011) p. 54-56. [[https://www.nature.com/articles/nri2902]].)) influenza,((Pleguezuelos et al. //Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study.// npj Vaccines **5.22**. (2020) [[https://www.nature.com/articles/s41541-020-0174-9]].)) cholera,((Haney et al. //Antibody-Based Correlates of Protection against Cholera: Analysis of a Challenge Study of a Cholera-Naive Population.// Clinical and Vaccine Immunology **24**. (2017) [[https://journals.asm.org/doi/pdf/10.1128/cvi.00098-17]].)) typhoid,((Darton et al. //Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.// PLOS Neglected Tropical Diseases. (2016) [[https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004926]].)) dengue,((Kirkpatrick et al. //The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.// Science Translational Medicine **8.330**. (2016) [[https://centerforimmunizationresearch.org/wp-content/uploads/2018/08/The-live-attenuated-dengue-vaccine-TV003-elicits-complete-protection-against-dengue-in-a-human-challenge-model.pdf]].)) and others.((Roestenberg et al. //Experimental Infection of Human Volunteers.// The Lancet Infectious Diseases **18.10**. (2018) [[https://scholarlypublications.universiteitleiden.nl/access/item%3A3005330/view]].)) | Dozens of human challenge trials have been approved by IRBs, including for malaria,((Sauerwein et al. //Experimental human challenge infections can accelerate clinical malaria vaccine development.// Nature Reviews Immunology **11**. (2011) p. 54-56. [[https://www.nature.com/articles/nri2902]].)) influenza,((Pleguezuelos et al. //Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study.// npj Vaccines **5.22**. (2020) [[https://www.nature.com/articles/s41541-020-0174-9]].)) cholera,((Haney et al. //Antibody-Based Correlates of Protection against Cholera: Analysis of a Challenge Study of a Cholera-Naive Population.// Clinical and Vaccine Immunology **24**. (2017) [[https://journals.asm.org/doi/pdf/10.1128/cvi.00098-17]].)) typhoid,((Darton et al. //Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.// PLOS Neglected Tropical Diseases. (2016) [[https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004926]].)) dengue,((Kirkpatrick et al. //The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.// Science Translational Medicine **8.330**. (2016) [[https://centerforimmunizationresearch.org/wp-content/uploads/2018/08/The-live-attenuated-dengue-vaccine-TV003-elicits-complete-protection-against-dengue-in-a-human-challenge-model.pdf]].)) and others.((Roestenberg et al. //Experimental Infection of Human Volunteers.// The Lancet Infectious Diseases **18.10**. (2018) [[https://scholarlypublications.universiteitleiden.nl/access/item%3A3005330/view]].)) |
| How much time in vaccine development could have been saved if fast challenge times were done? | How much time in vaccine development could have been saved if fast challenge times were done? |
| |
| To estimate this, we could assume that challenge trials replace phase 3 trials, in conjunction with a larger safety trial, and that all of the preparatory work could have been done by July 2020, when the phase 3 trials for Pfizer and Moderna began. Challenge trials could have been completed in two months.((Nguyen et al. //Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development.// Clinical Infectious Diseases **72.4**. (2021) p. 710–715. [[https://academic.oup.com/cid/article/72/4/710/5868014]].)) The actual phase 3 trials took four months.((The Pfizer trial started on July 27, 2020 and published results on November 18, 2020. \\ //About Our Landmark Trial.// Pfizer. (Accessed March 21, 2023) [[https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial]].)) We will estimate that challenge trials could have sped up vaccine development by two months. | To estimate this, we could assume that challenge trials replace phase 3 trials, in conjunction with a larger safety trial, and that all of the preparatory work could have been done by July 2020, when the phase 3 trials for Pfizer and Moderna began. Challenge trials could have been completed in two months.((Nguyen et al. //Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development.// Clinical Infectious Diseases **72.4**. (2021) p. 710–715. [[https://academic.oup.com/cid/article/72/4/710/5868014]].)) The actual phase 3 trials took four months.((The Pfizer trial started on July 27, 2020 and published results on November 18, 2020. This was an unusually short amount of time because the vaccine was unusually effective and the disease was unusually common. \\ //About Our Landmark Trial.// Pfizer. (Accessed March 21, 2023) [[https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial]].)) We will estimate that challenge trials could have sped up vaccine development by two months. |
| |
| A more aggressive (and speculative) strategy would be to skip the preparatory work. You do not need to manufacture the virus or figure out the right dose of virus if the challenge trial involves directly exposing the volunteers to someone who is currently sick with COVID-19. This is significantly more risky for the dozens of volunteers involved in the study, but it would make the process much faster. Once the scale of the crisis became apparent in March 2020, we could have decided to ignore medical ethics and adopt this strategy. We would have known which vaccines work two months later, in May 2020, 6 months earlier than what actually happened. This is a very speculative estimate because (1) I have not found a counterfactual plan describing the details of how this might have worked, (2) scaling up the manufacturing of the vaccine might have taken long enough for us not to have been able to realize these gains, and (3) public acceptance of the vaccine might have been lower if the vaccine development had seemed more rushed. | A more aggressive (and speculative) strategy would be to skip the preparatory work. You do not need to manufacture the virus or figure out the right dose of virus if the challenge trial involves directly exposing the volunteers to someone who is currently sick with COVID-19. This is significantly more risky for the dozens of volunteers involved in the study, but it would make the process much faster. Once the scale of the crisis became apparent in March 2020, we could have decided to ignore medical ethics and adopt this strategy. We would have known which vaccines work two months later, in May 2020, 6 months earlier than what actually happened. This is a very speculative estimate because (1) I have not found a counterfactual plan describing the details of how this might have worked, (2) scaling up the manufacturing of the vaccine might have taken long enough for us not to have been able to realize these gains, and (3) public acceptance of the vaccine might have been lower if the vaccine development had seemed more rushed. |
| In April 2022, the Institute for Progress estimated that the total cost of the pandemic to the US was \$10-22 trillion, including 1.1-1.4 million deaths.((Bruns & Teran. //Weighing the Cost of the Pandemic.// Institute for Progress. (2022) [[https://progress.institute/weighing-the-cost-of-the-pandemic/]].)) If this were spread evenly over the 25 months since March 2020 and challenge trials shortened the pandemic by 2 [or 6] months, this would have saved \$0.8-1.8 trillion [$2.4-5.3 trillion], including 90,000-110,000 deaths [260,000-340,000] deaths. This is likely an underestimate because the vaccine became widely available just after the worst part of the pandemic for the US. | In April 2022, the Institute for Progress estimated that the total cost of the pandemic to the US was \$10-22 trillion, including 1.1-1.4 million deaths.((Bruns & Teran. //Weighing the Cost of the Pandemic.// Institute for Progress. (2022) [[https://progress.institute/weighing-the-cost-of-the-pandemic/]].)) If this were spread evenly over the 25 months since March 2020 and challenge trials shortened the pandemic by 2 [or 6] months, this would have saved \$0.8-1.8 trillion [$2.4-5.3 trillion], including 90,000-110,000 deaths [260,000-340,000] deaths. This is likely an underestimate because the vaccine became widely available just after the worst part of the pandemic for the US. |
| |
| Another way to estimate how many lives would have been saved if the vaccine had come sooner is to compare the number of deaths before and after the vaccine. This is also an underestimate because the vaccine is not the only thing that changes: new variants arose and people took fewer precautions, partially in response to the vaccine and partially because they were tired of social distancing. During the first year of the pandemic, between March 15, 2020 and March 15, 2021,((The US had administered 100 million doses of vaccine by March 19, 2021 and over half of the United States had received at least one dose by April 18, 2021. \\ //A Timeline of COVID-19 Vaccine Developments in 2021.// American Journal of Managed Care. (2021) [[https://www.ajmc.com/view/a-timeline-of-covid-19-vaccine-developments-in-2021]].)) 540,000 people died from COVID-19 in the US. During the second year of the pandemic, 430,000 people died from COVID-19 in the US.((Mathieu et al. //Coronavirus (COVID-19) Deaths.// Our World in Data. (Accessed March 22, 2023) [[https://ourworldindata.org/covid-deaths]].)) There were about 10,000 fewer deaths per month with the vaccine than without the vaccine. If the vaccine were available 2 [or 6] months earlier, there could have been 20,000 [60,000] fewer deaths. | Another way to estimate how many lives would have been saved if the vaccine had come sooner is to compare the number of deaths before and after the vaccine. This is also an underestimate because the vaccine is not the only thing that changed: new variants arose and people took fewer precautions, partially in response to the vaccine and partially because they were tired of social distancing. During the first year of the pandemic, between March 15, 2020 and March 15, 2021,((The US had administered 100 million doses of vaccine by March 19, 2021 and over half of the United States had received at least one dose by April 18, 2021. \\ //A Timeline of COVID-19 Vaccine Developments in 2021.// American Journal of Managed Care. (2021) [[https://www.ajmc.com/view/a-timeline-of-covid-19-vaccine-developments-in-2021]].)) 540,000 people died from COVID-19 in the US. During the second year of the pandemic, 430,000 people died from COVID-19 in the US.((Mathieu et al. //Coronavirus (COVID-19) Deaths.// Our World in Data. (Accessed March 22, 2023) [[https://ourworldindata.org/covid-deaths]].)) There were about 10,000 fewer deaths per month with the vaccine than without the vaccine. If the vaccine were available 2 [or 6] months earlier, there could have been 20,000 [60,000] fewer deaths. |
| |
| For a rough estimate of the global amount of value resisted by slowing vaccine challenge trials, we could multiply the financial cost for the US by a factor of 4,((The US accounts for about 1/4 of the GDP of the world. \\ //GDP (current US\$).// The World Bank. (2021) [[https://data.worldbank.org/indicator/NY.GDP.MKTP.CD]].)) and the number of deaths by a factor of 6.((The US accounts for 1/6 of the confirmed deaths from COVID-19 in the world. The US has 1/24 of the global population, so if you think that this difference is mostly due to reporting, you could multiply the number of deaths by 24 instead.\\ Mathieu et al. //Coronavirus (COVID-19) Deaths.// Our World in Data. (Accessed March 22, 2023) [[https://ourworldindata.org/covid-deaths]].)) The result is trillions of dollars and hundreds of thousands or millions of lives lost. | For a rough estimate of the global amount of value resisted by slowing vaccine challenge trials, we could multiply the financial cost for the US by a factor of 4,((The US accounts for about 1/4 of the GDP of the world. \\ //GDP (current US\$).// The World Bank. (2021) [[https://data.worldbank.org/indicator/NY.GDP.MKTP.CD]].)) and the number of deaths by a factor of 6.((The US accounts for 1/6 of the confirmed deaths from COVID-19 in the world. The US has 1/24 of the global population, so if you think that this difference is mostly due to reporting, you could multiply the number of deaths by 24 instead.\\ Mathieu et al. //Coronavirus (COVID-19) Deaths.// Our World in Data. (Accessed March 22, 2023) [[https://ourworldindata.org/covid-deaths]].)) The result is trillions of dollars and hundreds of thousands or millions of lives lost. |
| The main actors which decide how quickly vaccine challenge trials occur are pharmaceutical companies and institutional review boards (IRBs). | The main actors which decide how quickly vaccine challenge trials occur are pharmaceutical companies and institutional review boards (IRBs). |
| |
| The two leading COVID-19 vaccine developers, Pfizer and Moderna, each had tens of billions of dollars of revenue from their COVID-19 vaccines((Pfizer reported \$36.8 billion in revenue from their vaccine, Comirnaty in 2021. [[https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2021/performance/]]. \\ | The two leading COVID-19 vaccine developers, Pfizer and Moderna, each had tens of billions of dollars of revenue from their COVID-19 vaccines((Pfizer reported \$36.8 billion in revenue from their vaccine, Comirnaty, in 2021. [[https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2021/performance/]]. \\ |
| Moderna reported $17.7 billion in revenue from their vaccine. [[https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx]].)) and had profit margins of 25%-60% during the pandemic.((Macrotrends for Pfizer: [[https://www.macrotrends.net/stocks/charts/PFE/pfizer/profit-margins]] and Moderna: [[https://www.macrotrends.net/stocks/charts/MRNA/moderna/profit-margins]].)) If one of them were able to roll out their vaccine two months earlier, they probably could have made billions of dollars of additional profit. They had a substantial incentive to make vaccines faster. | Moderna reported $17.7 billion in revenue from their vaccine. [[https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx]].)) and had profit margins of 25%-60% during the pandemic.((Macrotrends for Pfizer: [[https://www.macrotrends.net/stocks/charts/PFE/pfizer/profit-margins]] and Moderna: [[https://www.macrotrends.net/stocks/charts/MRNA/moderna/profit-margins]].)) If one of them were able to roll out their vaccine two months earlier, they probably could have made billions of dollars of additional profit. They had a substantial incentive to make vaccines faster. |
| |
| Trials can be slowed or stopped by IRBs, which have very different incentives. I am describing the situation in the US; similar ethics committees exist in other countries as well. | Trials can be slowed or stopped by IRBs, which have very different incentives. This is a description of the situation in the US; similar ethics committees exist in other countries as well. |
| |
| There are two types of IRBs: 'Central' or 'independent' IRBs are for profit enterprises which charge investigators for reviewing their proposed research. 'Local' IRBs are associated with the institution where the research is done and seem to be significantly more common.((Moon. //The History and Role of Institutional Review Boards: A Useful Tension.// AMA Journal of Ethics (2009) [[https://journalofethics.ama-assn.org/article/history-and-role-institutional-review-boards-useful-tension/]].)) Oversight of IRB is done by the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP). Their audits encourage detailed documentation of all parts of the investigation.((Gunsalus et al. //Mission Creep in the IRB World.// Science **312.5779**. (2006) p. 1441. [[https://www.science.org/doi/full/10.1126/science.1121479]].)) Other than these audits, there are few incentives acting on IRBs, especially local IRBs. They do not have to justify their decisions and their decisions cannot be appealed.((Bagley. //Should IRBs be dismantled? The Incidental Economist.// (2015) [[http://theincidentaleconomist.com/wordpress/should-irbs-be-dismantled/]].)) If research results in an important discovery, the research institution and investigators gain prestige, but this is rarely shared with the IRB which approved it. The IRB is much more likely to gain infamy if it approves research which is considered unethical. The result is a form of asymmetric justice: IRBs face more criticism for their mistakes than praise for their successes.((Zvi Mowshowitz. //Asymmetric Justice.// Don’t Worry About the Vase. (2019) [[https://thezvi.wordpress.com/2019/04/25/asymmetric-justice/]].)) In these circumstances, it is not surprising that IRBs are often cautious and insist on justifying and documenting everything. | There are two types of IRBs: 'Central' or 'independent' IRBs are for profit enterprises which charge investigators for reviewing their proposed research. 'Local' IRBs are associated with the institution where the research is done and seem to be significantly more common.((Moon. //The History and Role of Institutional Review Boards: A Useful Tension.// AMA Journal of Ethics (2009) [[https://journalofethics.ama-assn.org/article/history-and-role-institutional-review-boards-useful-tension/2009-04]].)) Oversight of IRBs is done by the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP). Their audits encourage detailed documentation of all parts of the investigation.((Gunsalus et al. //Mission Creep in the IRB World.// Science **312.5779**. (2006) p. 1441. [[https://www.science.org/doi/full/10.1126/science.1121479]].)) Other than these audits, there are few incentives acting on IRBs, especially local IRBs. They do not have to justify their decisions and their decisions cannot be appealed.((Bagley. //Should IRBs be dismantled? The Incidental Economist.// (2015) [[http://theincidentaleconomist.com/wordpress/should-irbs-be-dismantled/]].)) If research results in an important discovery, the research institution and investigators gain prestige, but this is rarely shared with the IRB which approved it. The IRB is much more likely to gain infamy if it approves research which is considered unethical. The result is a form of asymmetric justice: IRBs face more criticism for their mistakes than praise for their successes.((Zvi Mowshowitz. //Asymmetric Justice.// Don’t Worry About the Vase. (2019) [[https://thezvi.wordpress.com/2019/04/25/asymmetric-justice/]].)) In these circumstances, it is not surprising that IRBs are often cautious and insist on justifying and documenting everything. |
| |
| During the pandemic, there was also significant political pressure to make vaccines available faster. Operation Warp Speed provided funding for vaccine research and preordered hundreds of millions of doses of promising vaccine candidates so vaccine manufacturing could scale up before the vaccines were approved.((//Explaining Operation Warp Speed.// US Department of Health and Human Services. (2020) [[https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus-lpha/pdf/fact-sheet-operation-warp-speed.pdf]].)) These efforts probably shortened the time before vaccines were widely available by months. However, the FDA and Pfizer proved to be effective at resisting political pressure to get the vaccines approved before Election Day.((Regalado. //One doctor’s campaign to stop a covid-19 vaccine being rushed through before Election Day.// MIT Technology Review. (2020) [[https://www.technologyreview.com/2020/10/19/1010646/campaign-stop-covid-19-vaccine-trump-election-day/]].)) | During the pandemic, there was also significant political pressure to make vaccines available faster. Operation Warp Speed provided funding for vaccine research and preordered hundreds of millions of doses of promising vaccine candidates so vaccine manufacturing could scale up before the vaccines were approved.((//Explaining Operation Warp Speed.// US Department of Health and Human Services. (2020) [[https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus-lpha/pdf/fact-sheet-operation-warp-speed.pdf]].)) These efforts probably shortened the time until vaccines were widely available by months. However, the FDA and Pfizer proved to be effective at resisting political pressure to get the vaccines approved before Election Day.((Regalado. //One doctor’s campaign to stop a covid-19 vaccine being rushed through before Election Day.// MIT Technology Review. (2020) [[https://www.technologyreview.com/2020/10/19/1010646/campaign-stop-covid-19-vaccine-trump-election-day/]].)) |
| |
| While pharmaceutical companies and the public have incentives that encourage them to quickly approve human challenge trials, and vaccines more generally, IRBs and the FDA are insulated from these incentives. This allows them to slow or block challenge trials, partially resisting the technological temptation. | While pharmaceutical companies and the public have incentives that encourage them to quickly approve human challenge trials, and vaccines more generally, IRBs and the FDA are insulated from these incentives. This allows them to slow or block challenge trials, partially resisting the technological temptation. |
